Angelini Pharma bets $4.1bn on rare neurology scale with Catalyst Pharmaceuticals
Angelini gains U.S. rare disease scale. Catalyst gets certainty, but Firdapse concentration keeps the real test ahead.
What does Swissmedic approval of Santhera’s AGAMREE mean for long-term steroid treatment in Duchenne muscular dystrophy?
Swissmedic approves Santhera’s AGAMREE for Duchenne muscular dystrophy. Find out how vamorolone could reshape long-term steroid treatment strategies.